Lefamulin
- Generic Name
- Lefamulin
- Brand Names
- Xenleta
- Drug Type
- Small Molecule
- Chemical Formula
- C28H45NO5S
- CAS Number
- 1061337-51-6
- Unique Ingredient Identifier
- 21904A5386
- Background
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synth...
- Indication
Lefamulin is indicated to treat adults diagnosed with community-acquired bacterial pneumonia (CABP) that is caused by susceptible bacteria. Its use should be reserved for confirmed susceptible organisms or a high probability of infection with susceptible organisms. The list of susceptible bacteria includes Streptococcus pneumoniae, Staphylococcus aureus (met...
- Associated Conditions
- Community acquired pneumonia caused by Streptococcus Pneumoniae, Haemophilus Influenzae, Methicillin-Sensitive Staphylococcus Aureus Infection, Legionella Pneumophila Infections, Mycoplasma pneumoniae infection, Chlamydophila Pneumoniae Infections
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.